JP7668273B2 - Ｂｃｌ６阻害剤としての［１，４］オキサゼピノ［２，３－ｃ］キノリノン誘導体 - Google Patents

Ｂｃｌ６阻害剤としての［１，４］オキサゼピノ［２，３－ｃ］キノリノン誘導体 Download PDF

Info

Publication number
JP7668273B2
JP7668273B2 JP2022522065A JP2022522065A JP7668273B2 JP 7668273 B2 JP7668273 B2 JP 7668273B2 JP 2022522065 A JP2022522065 A JP 2022522065A JP 2022522065 A JP2022522065 A JP 2022522065A JP 7668273 B2 JP7668273 B2 JP 7668273B2
Authority
JP
Japan
Prior art keywords
difluoro
methyl
amino
cyclopropyl
oxazepino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022522065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551950A (ja
JP2022551950A5 (enExample
Inventor
ベレニー，ベンジャミン・リチャード
ブレナン，アルフィー
チェン，カイ・ミン・ジャック
デイヴィス，オーウェン・アレクサンダー
ハーンデン，アリス・クレア
ヘルダー，スウェン
ハックヴェール，ローズマリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Institute of Cancer Research: Royal Cancer Hospital
Original Assignee
The Institute of Cancer Research: Royal Cancer Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Institute of Cancer Research: Royal Cancer Hospital filed Critical The Institute of Cancer Research: Royal Cancer Hospital
Publication of JP2022551950A publication Critical patent/JP2022551950A/ja
Publication of JP2022551950A5 publication Critical patent/JP2022551950A5/ja
Application granted granted Critical
Publication of JP7668273B2 publication Critical patent/JP7668273B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022522065A 2019-10-14 2020-10-14 Ｂｃｌ６阻害剤としての［１，４］オキサゼピノ［２，３－ｃ］キノリノン誘導体 Active JP7668273B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201914860A GB201914860D0 (en) 2019-10-14 2019-10-14 Inhibitor compounds
GB1914860.0 2019-10-14
PCT/GB2020/052588 WO2021074620A1 (en) 2019-10-14 2020-10-14 [1,4]oxazepino[2,3-c]qui noli none derivatives as blc6 inhibitors

Publications (3)

Publication Number Publication Date
JP2022551950A JP2022551950A (ja) 2022-12-14
JP2022551950A5 JP2022551950A5 (enExample) 2023-10-19
JP7668273B2 true JP7668273B2 (ja) 2025-04-24

Family

ID=68619494

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022522065A Active JP7668273B2 (ja) 2019-10-14 2020-10-14 Ｂｃｌ６阻害剤としての［１，４］オキサゼピノ［２，３－ｃ］キノリノン誘導体

Country Status (13)

Country Link
US (1) US12528826B2 (enExample)
EP (1) EP4045510B1 (enExample)
JP (1) JP7668273B2 (enExample)
KR (1) KR20220083761A (enExample)
CN (1) CN114650995A (enExample)
AU (1) AU2020365518B2 (enExample)
CA (1) CA3157716A1 (enExample)
ES (1) ES3047908T3 (enExample)
GB (1) GB201914860D0 (enExample)
IL (1) IL292182B2 (enExample)
MX (1) MX2022004419A (enExample)
WO (1) WO2021074620A1 (enExample)
ZA (1) ZA202203520B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296734B2 (en) 2018-04-13 2025-06-01 The Institute Of Cancer Res Royal Cancer Hospital Bcl6 inhibitors
GB201914860D0 (en) 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds
MX2022004526A (es) 2019-10-17 2022-07-21 Arvinas Operations Inc Moléculas bifuncionales que contienen una porción de unión a la ligasa de ubiquitina e3 unida a una porción de direccionamiento a bcl6.
CN118388454A (zh) 2021-04-16 2024-07-26 阿尔维纳斯运营股份有限公司 Bcl6蛋白水解的调节剂和其相关使用方法
WO2023240038A1 (en) * 2022-06-06 2023-12-14 Treeline Biosciences, Inc. Tricyclic quinolone bcl6 bifunctional degraders
AU2023295387A1 (en) 2022-06-13 2025-01-09 Treeline Biosciences, Inc. 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders
KR20250023483A (ko) 2022-06-13 2025-02-18 트리라인 바이오사이언시스, 인크. 퀴놀론 bcl6 이작용성 분해제
WO2024228505A1 (ko) * 2023-05-03 2024-11-07 인제대학교 산학협력단 Btk 분해제 및 bcl-6 분해제를 포함하는 암의 예방 또는 치료용 약학적 조성물
TW202525814A (zh) * 2023-09-01 2025-07-01 美商樹線生物科學公司 三環喹啉酮ｂｃｌ６雙功能降解劑

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015526395A (ja) 2012-06-18 2015-09-10 ダート・ニューロサイエンス・（ケイマン）・リミテッド 置換ピリジンアゾロピリミジン−５−（６ｈ）−オン化合物
JP2017536409A (ja) 2014-12-06 2017-12-07 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
WO2018108704A1 (en) 2016-12-13 2018-06-21 Boehringer Ingelheim International Gmbh New 6-amino-quinolinone compounds and derivatives as bcl6 inhibitors
WO2018215798A1 (en) 2017-05-26 2018-11-29 Cancer Research Technology Limited 2-quinolone derived inhibitors of bcl6

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0259572A (ja) 1988-08-23 1990-02-28 Mitsubishi Kasei Corp ベンズイミダゾロン誘導体又はその塩類
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
EP1144387A1 (en) 1998-12-04 2001-10-17 Neurosearch A/S New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
TR200200161T2 (tr) 1999-07-21 2002-05-21 Fujisawa Pharmaceutical Co. Ltd. Benzimidazol türevleri ve onların fosfodiesteraz olarak kullanımı.
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
WO2001094311A1 (en) 2000-06-08 2001-12-13 Mitsubishi Pharma Corporation Cytoprotectors
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
CA2656507C (en) 2006-07-17 2012-03-20 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
WO2008066887A2 (en) 2006-11-30 2008-06-05 Albert Einstein College Of Medicine Of Yeshiva University Small molecule inhibitors of bcl6
US8686008B2 (en) 2007-08-16 2014-04-01 The University Of Mississippi Highly selective sigma receptor ligands
WO2009063240A1 (en) 2007-11-16 2009-05-22 Arrow Therapeutics Limited 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase
WO2009097578A1 (en) 2008-02-01 2009-08-06 Takeda Pharmaceutical Company Limited Oxim derivatives as hsp90 inhibitors
PL2364983T3 (pl) 2008-11-11 2014-04-30 Jeil Pharmaceutical Co Ltd Nowa pochodna tricykliczna lub jej farmaceutycznie dopuszczalne sole, sposób jej wytwarzania, oraz zawierająca ją kompozycja farmaceutyczna
PL2389372T3 (pl) 2009-01-23 2016-02-29 Rigel Pharmaceuticals Inc Kompozycje i sposoby hamowania szlaku JAK
CN102791131A (zh) 2010-01-13 2012-11-21 葛兰素史密斯克莱有限责任公司 化合物和方法
ES2698847T3 (es) 2011-07-07 2019-02-06 Merck Patent Gmbh Azaheterociclos sustituidos para el tratamiento del cáncer
CN105143215B (zh) 2013-03-05 2017-12-08 豪夫迈·罗氏有限公司 布鲁顿氏酪氨酸激酶抑制剂
US9943506B2 (en) 2013-06-17 2018-04-17 Cornell University BCL6 inhibitors as anticancer agents
CN105017159B (zh) 2014-04-28 2019-05-17 四川大学 5-氟-2,4-二取代氨基嘧啶衍生物及其制备方法和用途
ES2914099T3 (es) 2014-08-25 2022-06-07 Salk Inst For Biological Studi Inhibidores novedosos de ULK1 y métodos de uso de los mismos
US20160060260A1 (en) 2014-08-29 2016-03-03 Board Of Regents, The University Of Texas System Bromodomain inhibitors for treating disease
WO2017007658A1 (en) 2015-07-07 2017-01-12 Rigel Pharmaceuticals, Inc. A combination for immune mediated cancer treatment
EP3630291B9 (en) 2017-05-26 2024-05-29 Cancer Research Technology Limited Benzimidazolone derived inhibitors of bcl6
IL296734B2 (en) * 2018-04-13 2025-06-01 The Institute Of Cancer Res Royal Cancer Hospital Bcl6 inhibitors
GB201819136D0 (en) 2018-11-23 2019-01-09 Cancer Research Tech Ltd Inhibitor compounds
GB201914860D0 (en) 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015526395A (ja) 2012-06-18 2015-09-10 ダート・ニューロサイエンス・（ケイマン）・リミテッド 置換ピリジンアゾロピリミジン−５−（６ｈ）−オン化合物
JP2017536409A (ja) 2014-12-06 2017-12-07 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
WO2018108704A1 (en) 2016-12-13 2018-06-21 Boehringer Ingelheim International Gmbh New 6-amino-quinolinone compounds and derivatives as bcl6 inhibitors
WO2018215798A1 (en) 2017-05-26 2018-11-29 Cancer Research Technology Limited 2-quinolone derived inhibitors of bcl6

Also Published As

Publication number Publication date
JP2022551950A (ja) 2022-12-14
CA3157716A1 (en) 2021-04-22
AU2020365518A1 (en) 2022-04-14
US20240217987A1 (en) 2024-07-04
ZA202203520B (en) 2025-09-25
AU2020365518B2 (en) 2026-04-23
GB201914860D0 (en) 2019-11-27
EP4045510A1 (en) 2022-08-24
KR20220083761A (ko) 2022-06-20
ES3047908T3 (en) 2025-12-05
EP4045510B1 (en) 2025-07-30
IL292182B2 (en) 2026-06-01
MX2022004419A (es) 2022-08-08
IL292182A (en) 2022-06-01
WO2021074620A1 (en) 2021-04-22
WO2021074620A9 (en) 2021-06-17
IL292182B1 (en) 2026-02-01
US12528826B2 (en) 2026-01-20
CN114650995A (zh) 2022-06-21
EP4045510C0 (en) 2025-07-30

Similar Documents

Publication Publication Date Title
EP4045510B1 (en) [1,4]oxazepino[2,3-c]quinolinone derivatives as blc6 inhibitors
US12486285B2 (en) BCL6 inhibitors
US11161839B2 (en) 2-quinolone derived inhibitors of BCL6
KR20190129936A (ko) Ｐｒｍｔ５-매개성 질환의 치료 또는 예방에 유용한 화합물
CN110621675A (zh) 用于治疗增殖性疾病的三环化合物
WO2020104820A1 (en) Substituted benzimidazolones as anti-cancer agents
US20230203029A1 (en) Naphthyridine compounds as inhibitors of mer tyrosine kinase and axl tyrosine kinase
US20240293392A1 (en) Inhibitor compounds
WO2025262192A1 (en) Quinazoline derivatives suitable for use as werner syndrome helicase protein inhibitors
CN120858100A (zh) 抑制性化合物
JP2024543183A (ja) 阻害剤化合物
HK40081687A (en) [1,4]oxazepino[2,3‑c]quinolinone derivatives as blc6 inhibitors
HK40081687B (en) [1,4]oxazepino[2,3‑c]quinolinone derivatives as blc6 inhibitors
EA047672B1 (ru) Производные [1,4]оксазепино[2,3-c]хинолинона в качестве ингибиторов bcl6
HK40046058B (en) Bcl6 inhibitors
HK40046058A (en) Bcl6 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250318

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250414

R150 Certificate of patent or registration of utility model

Ref document number: 7668273

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150